National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

  • Selexipag (Uptravi®) - May 21, 2018

    The NCPE recommends that selexipag not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Evolocumab (Repatha®) - May 16, 2018

    The NCPE recommends that evolocumab should not be reimbursed unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Naltrexone / bupropion (Mysimba®) - May 9, 2018

    The NCPE recommends that naltrexone/bupropion (Mysimba ®) should not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Osimertinib (Tagrisso®) - May 3, 2018

    The NCPE recommends that osimertinib (Tagrisso®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma - May 3, 2018

    The NCPE recommends that obinutuzumab (Gazyvaro®) in combination with chemotherapy followed by obinutuzumab maintenance therapy for this indication should not be considered for reimbursement, unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Eliglustat (Cerdelga®) - April 25, 2018

    The NCPE recommends that eliglustat (Cerdelga ®) should not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria as specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Blinatumomab (Blincyto®) - April 16, 2018

    The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

  • Teduglutide (Revestive®) - March 16, 2018

    The NCPE does not recommend reimbursement of Teduglutide (Revestive®) for the treatment of patients aged 1 year and above with short bowel syndrome.

  • Patient Education Programme - December 19, 2017

    The NCPE are delighted to facilitate  the delivery of the HTA module of the IPPOSI Pilot Patient Education Programme, commencing this Monday 22nd January. This module will provide students with a detailed knowledge of the principals of HTA, and has been adapted by the NCPE to provide particular insight into the practice of HTA in […]

  • Nusinersin (Spinraza®) - December 19, 2017

    The NCPE does not recommend the reimbursement of Nusinersen (Sprinraza®) for the treatment of 5q spinal muscular atrophy (SMA) at the submitted price.